Belite Bio (BLTE) Competitors

Belite Bio (NASDAQ:BLTE) and Blueprint Medicines (NASDAQ:BPMC) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, risk, media sentiment, profitability, community ranking, dividends, valuation, institutional ownership and earnings.

Do institutionals and insiders believe in BLTE or BPMC?

0.5% of Belite Bio shares are held by institutional investors. 13.3% of Belite Bio shares are held by insiders. Comparatively, 4.2% of Blueprint Medicines shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Do analysts rate BLTE or BPMC?

Belite Bio presently has a consensus target price of $96.67, indicating a potential upside of 58.21%. Blueprint Medicines has a consensus target price of $129.35, indicating a potential upside of 1.10%. Given Belite Bio's stronger consensus rating and higher probable upside, equities analysts plainly believe Belite Bio is more favorable than Blueprint Medicines.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Belite Bio	0 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	3.00
Blueprint Medicines	0 Sell rating(s)	16 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.32

Does the media refer more to BLTE or BPMC?

In the previous week, Blueprint Medicines had 5 more articles in the media than Belite Bio. MarketBeat recorded 16 mentions for Blueprint Medicines and 11 mentions for Belite Bio. Belite Bio's average media sentiment score of 0.69 beat Blueprint Medicines' score of 0.56 indicating that Belite Bio is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Belite Bio	3 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Blueprint Medicines	6 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Which has higher valuation and earnings, BLTE or BPMC?

Belite Bio has higher earnings, but lower revenue than Blueprint Medicines. Blueprint Medicines is trading at a lower price-to-earnings ratio than Belite Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Belite Bio	N/A	N/A	-$31.63M	-$1.36	-44.93
Blueprint Medicines	$562.12M	14.70	-$67.09M	-$2.47	-51.80

Which has more volatility & risk, BLTE or BPMC?

Belite Bio has a beta of -1.44, meaning that its share price is 244% less volatile than the S&P 500. Comparatively, Blueprint Medicines has a beta of 0.84, meaning that its share price is 16% less volatile than the S&P 500.

Is BLTE or BPMC more profitable?

Belite Bio has a net margin of 0.00% compared to Blueprint Medicines' net margin of -13.19%. Belite Bio's return on equity of -31.94% beat Blueprint Medicines' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Belite Bio	N/A	-31.94%	-30.73%
Blueprint Medicines	-13.19%	-77.49%	-20.84%

Does the MarketBeat Community favor BLTE or BPMC?

Blueprint Medicines received 518 more outperform votes than Belite Bio when rated by MarketBeat users. However, 94.74% of users gave Belite Bio an outperform vote while only 66.99% of users gave Blueprint Medicines an outperform vote.

Company	Underperform	Outperform
Belite Bio	Outperform Votes 36 94.74%	Underperform Votes 2 5.26%
Blueprint Medicines	Outperform Votes 554 66.99%	Underperform Votes 273 33.01%

Summary

Belite Bio beats Blueprint Medicines on 11 of the 18 factors compared between the two stocks.